Reference: WHO PMTCT Integrated Guidelines / CDC HIV Prevention Framework.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Clinical Uses
Guiding the mode of delivery (Vaginal vs Cesarean) in pregnant individuals living with HIV.
Determining the necessity for intrapartum intravenous Zidovudine (AZT).
Preventing Mother-to-Child Transmission (PMTCT) of HIV during labor and delivery.
Success Rate
With strict adherence to antiretroviral therapy (ART) and an undetectable viral load appropriately managed at delivery, the perinatal transmission rate of HIV drops from ~25% to less than 1%.
Section 2
Formula & Logic
Viral Load (VL) Thresholds near Delivery (34-36 wks)
VL < 50 copies/mL (Undetectable)
Vaginal delivery indicated. IV AZT NOT required (though some protocols use cutoffs like >50 or >1,000 for AZT).
VL 50 – 999 copies/mL
Vaginal delivery generally supported. IV AZT IS recommended intrapartum.
VL ≥ 1,000 copies/mL (or unknown)
Scheduled Cesarean delivery at 38 weeks. IV AZT IS required.
Section 3
Pearls/Pitfalls
Critical Intrapartum Rules
If viral load is strictly undetectable, avoiding artificial rupture of membranes (AROM), fetal scalp electrodes (FSE), and operative vaginal delivery is no longer absolutely mandated, but still strongly cautioned.
Avoid Methergine (methylergonovine) for postpartum hemorrhage routine prophylaxis if the patient is on a Protease Inhibitor (e.g., Ritonavir, Darunavir) or Cobicistat. Extreme vasoconstriction and catastrophic ischemia can occur due to CYP3A4 inhibition.
The Breastfeeding Shift (2023 Updates)
Historically, breastfeeding was an absolute contraindication for HIV-positive mothers in resource-rich settings. Modern DHHS guidelines now explicitly state that if a mother is virologically suppressed (undetectable) and strongly desires to breastfeed, providers should NOT contact Child Protective Services, but instead offer patient-centered, shared decision-making support.
Section 4
Next Steps
Intrapartum Zidovudine (AZT) Dosing
01
Required if VL >1,000, 50-999, or unknown.
02
Loading Dose: 2 mg/kg IV over 1 hour.
03
Maintenance: 1 mg/kg/hour IV continuous infusion.
04
Target: Initiate 3 hours prior to scheduled C-section or immediately upon admission in labor.
05
Continue until umbilical cord clamping.
Section 5
Evidence Appraisal
Primary Authority
Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission.
Department of Health and Human Services (DHHS). • NIH.. 2023;The absolute gold standard continuously-updating living document strictly governing all HIV management in pregnancy in the United States.
Section 6
Literature
PACTG 076
The Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 published in 1994 was the revolutionary placebo-controlled trial that proved Zidovudine could prevent maternal-fetal transmission, fundamentally changing the trajectory of the global AIDS pandemic.
